News
![NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding](https://pharmaphorum.com/wp-content/uploads/2019/08/NICE’s-track-record-in-cancer-drugs-the-impact-of-the-CDF-and-the-role-of-interim-funding.jpg)
BMS buys into Volastra's cancer expertise with $1.1bn allian...
Bristol-Myers Squibb is the first big pharma to strike a deal with Volastra Therapeutics, a start-up that has developed a drug discovery platform based on chromosomal instability (CIN), a c